PROPAPHENON: CLINICAL PHARMACOLOGY AND EFFICACY IN SUPRAVENTRICULАR TACHYARRHYTHMIAS (PART 1)
Abstract
Propaphenon: clinical pharmacology and efficacy in supraventriculаr tachyarrhythmias (Part 1).
About the Authors
D. V. Preobrazhensky
Медицинский центр Управления делами Президента Российской Федерации; Кардиологический научно- производственный комплекс МЗРФ, Москва
Russian Federation
Russian Federation
A. V. Marenich
Медицинский центр Управления делами Президента Российской Федерации; Кардиологический научно- производственный комплекс МЗРФ, Москва
Russian Federation
Russian Federation
T. A. Andreychenko
Медицинский центр Управления делами Президента Российской Федерации; Кардиологический научно- производственный комплекс МЗРФ, Москва
Russian Federation
Russian Federation
V. G. Kiktev
Медицинский центр Управления делами Президента Российской Федерации; Кардиологический научно- производственный комплекс МЗРФ, Москва
Russian Federation
Russian Federation
B. A. Sidorenko
Медицинский центр Управления делами Президента Российской Федерации; Кардиологический научно- производственный комплекс МЗРФ, Москва
Russian Federation
Russian Federation
References
1. цепторов ангиотензина II. Клиническаяфармакологияитера- пия, 2000, том 9, № 5, с.86-96.
2. Argenziano L., Trimarco B. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin, 1999;15(1):9-14.
3. Brooks D.P., Ruffolo R.R. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure. J. Hypertens. Suppl. 1999;17(2):S27-32.
4. Edvards R.M., Aiyar N., Ohlstein E.H. et al. Pharmacologic characterization of nonpeptide angiotensin II receptor antagonist, SK&f1085666. J. Pharmacol. Exp. Ther., 1992, 260:175-181.
5. Gavras I., Gavras H. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr. Med. Res. Opin. 1999;15(1):15-24.
6. Gradman A.H., Gray J., Maggiacomo F., Punzi H., White W.B. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group. Clin. Ther., 1999;21(3):442-453.
7. Hedner T., Himmelmann A. For the Eprosartan Multinational Study Group. The efficacy and tolerance of once and twice daily doses of eprosartan in essential hypertension. J. Hypertens. 1999; 17:129-136.
8. Ilson B.E, Boike S.C., Martin D.E. et al. A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin-II At1 -receptor antagonist in sodium-replete healthy men. Clin Pharmacol Ther, 1997. 63:471-481.
9. Ilson B.E., Martin D.E., . The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension. J. Clin. Pharmacol., 1998;38(5):437-441.
10. Kazierad D.J., Martin D.E., Ilson B. et al. Eprosartan does not affect the pharmacodynamics of warfarin. J. Clin. Pharmacol. 1998; 38:649-653.
11. Martin D.E., DeCherney G.S., Ilson B.E., Jones B.A., Boike S.C., Freed M.I., Jorkasky D.K. Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus. J. Clin. Pharmacol., 1997; 37(2):155-159.
12. Martin D.E., Tompson D., Boike S.C. et al. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers. Br. J. Clin. Pharmacol. 1997; 43:661-664.
13. Ohlstein E.H., Brooks D.P., Feuerstein G.Z., Ruffolo R.R. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology, 1997;55(5):244-51.
14. Oparil S. Eprosartan versus enalapril in hypertensive patients with angiotensin-converting enzyme inhibitor cough. Curr. Ther. Res., 1999; 60(1):1-14.
15. Ponticelli C., for the Eprosartan Study Group. Comparison of the efficacy of eprosartan and enalapril in patients with severe hypertension. Am. J. Hypertens. 1997; 10:128A.
16. Price D.A., De’Olivera J.M., Fisher N.D., Hollenberg N.K. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension, 1997, 30:240-246.
17. Puig J.G., Mateos F., Buno A., Ortega R., Rodriguez F., Dal-Re. R. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J. Hypertens., 1999;17(7):1033-1039.
18. Tenero D.M., Martin D.E., Ilson B.E. et al Effect ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers. Ann. Pharmacother., 1998;32:304-308.
19. Tsuda K., Tsuda S., Ura M. et al. Inhibitory actions of captopril on norepinephrine release from adrenergic nerve endings in spontaneously hyperetensive rats. Jpn. Heart J., 1988, 29:475-483.
20. Weber M. Clinical efficacy of eprosartan. Pharmacotherapy. 1999; 19(4, part 2):95S-101S.
21. Ziogas J. Cunnane T.C. An electrophisiological study of the actions of angiotensin II at sympathetic neuroeffector junction in guinea pig vas deferens. Br. J. Pharmacol. 1991, 103:1196-1202.
Review
For citations:
Preobrazhensky D.V., Marenich A.V., Andreychenko T.A., Kiktev V.G., Sidorenko B.A. PROPAPHENON: CLINICAL PHARMACOLOGY AND EFFICACY IN SUPRAVENTRICULАR TACHYARRHYTHMIAS (PART 1). Russian Journal of Cardiology. 2001;(4):93-98. (In Russ.)
Views:
288
Email this article 